Adiponectin and interlukin-10 in patients with liver diseases before and after liver transplantation

Abstract

Background/Aims: Hepatitis C virus (HCV) infection is a global blood-borne disease with the highest prevalence in Egypt. This study was carried out to evaluate the prevalence of adiponectin, Interleukin-10 levels in liver diseases and to identify the potential role of adipocyte derived adiponectin in patients with end stage before and after liver transplantation. Subject & method: The study population included 69 subjects classified as follow: Control group (G1) healthy individuals, group (G2) Anti HCV +ve & HCV RNA +ve by PCR, group (G3) Anti-HCV +ve H before liver transplantation (G4b) and after one week of liver transplantation (G4a). Result: Adiponectin levels showed highly significant decrease in G2 (P <0.002), G3 showed insignificant decrease (P<0.6), G4b showed highly significant increased (P <0.0001) and G4a showed insignificant decrease (P<0.08) compared with control group G1. IL-10 levels showed highly significant increase in patients groups (G2, G3, G4b and G4a) as compared with control group (P<0.0001). Conclusion: Adiponectin and IL-10 may be used as biomarker and/or a mediator of inflammatory states in liver diseases in patients with chronic hepatitis C. We suggest that high adiponectin and IL-10 levels in chronic liver disease before liver transplantation might reflect one of the body’s anti-inflammatory mechanisms in chronic liver diseases.